Preclinical Studies Comparing Efficacy and Toxicity of DNA Repair Inhibitors, Olaparib, and AsiDNA, in the Treatment of Carboplatin-Resistant Tumors

Preclinical Studies Comparing Efficacy and Toxicity of DNA Repair Inhibitors, Olaparib, and AsiDNA, in the Treatment of Carboplatin-Resistant Tumors

Purpose: Carboplatin is used to treat many cancers, but occurrence of drug resistance and its high toxicity remain a clinical hurdle limiting its efficacy. We compared the efficacy and toxicity of DNA repair inhibitors olaparib or AsiDNA administered alone or in combination with carboplatin. Olapari...

Full description

Bibliographic Details
Main Authors: Nirmitha I. Herath, Nathalie Berthault, Sylvain Thierry, Wael Jdey, Marie-Christine Lienafa, Françoise Bono, Patricia Noguiez-Hellin, Jian-Sheng Sun, Marie Dutreix
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-11-01
Series:Frontiers in Oncology
Subjects:
DNA repair inhibitors
carboplatin
AsiDNA
efficacy and toxicity
resistance
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.01097/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.01097/full

Similar Items